34th week of 2011 patent applcation highlights part 37 |
Patent application number | Title | Published |
20110206629 | CLEANSING COMPOSITION - The present invention is related to an aqueous cleansing composition for keratin fibres, especially human hair, comprising at least one amino acid surfactant, and a cationic polymer. Accordingly, the object of the present invention is an aqueous cleansing composition comprising at least one amino acid surfactant of structure (I) wherein R | 2011-08-25 |
20110206630 | SURFACTANT AND CLEANING COMPOSITIONS COMPRISING MICROBIALLY PRODUCED BRANCHED FATTY ALCOHOLS - The invention provides a surfactant and/or a cleaning composition comprising a microbially produced branched fatty alcohol or a derivative thereof. The invention also provides a household cleaning composition and a personal or pet care cleaning composition comprising a microbially produced branched fatty alcohol or a derivative thereof. | 2011-08-25 |
20110206631 | ION BINDING POLYMERS AND USES THEREOF - The present invention provides methods and compositions for the treatment of ion imbalances. In particular, the invention provides compositions comprising potassium binding polymers and pharmaceutical compositions thereof. Methods of use of the polymeric and pharmaceutical compositions for therapeutic and/or prophylactic benefits are disclosed herein. Examples of these methods include the treatment of hyperkalemia, such as hyperkalemia caused by renal failure and/or the use of hyperkalemia causing drugs. | 2011-08-25 |
20110206632 | Synthesis of zinc acrylate copolymer from acid functional copolymer, zinc pyrithione, and copper compound - Disclosed is a composition containing zinc ester functional polymer and particulate copper pyrithione, wherein the particles have an average aspect ratio within a range of from about 8 to about 15, where the zinc ester functional polymer and the copper pyrithione are obtained by reacting an acid functional polymer with zinc pyrithione and a copper salt or a copper carboxylate. Also disclosed is an antifouling coating containing such a composition. | 2011-08-25 |
20110206633 | POLYMER CONJUGATES OF CD-NP PEPTIDES - The invention provides CD-NP peptides that are chemically modified by covalent attachment of a water soluble oligomer. A conjugate of the invention, when administered by any of a number of administration routes, exhibits characteristics that are different from the characteristics of the peptide not attached to the water soluble oligomer. | 2011-08-25 |
20110206634 | COMPOSITE MATERIAL FOR TISSUE REPAIR - The present disclosure provides a biocompatible composite and method for its use in repairing tissue defects, including defects in cartilage. The biocompatible composite includes a fibrous polymeric component and a polymerizable agent, which is capable of forming the biocompatible composite in situ at the site of a tissue defect. In embodiments, the repair site at which the biocompatible composite is to be applied may be treated with a priming agent, permitting polymerization of the polymerizable agent to the tissue located at the repair site. | 2011-08-25 |
20110206635 | USES OF IL-12 IN HEMATOPOIESIS - Methods for enhancing or stimulating hematopoiesis including the step of administering Interleukin-12 (IL-12) to yield hernatopoietic recovery in a mammal in need. Preferred methods include the step of administering IL-12 as an adjuvant therapy to alleviate the hematopoietic toxicities associated with one or more treatment regimens used to combat a disease state. Other methods include administering IL-12 to ameliorate various hematopoietic deficiencies. Still other methods are directed to uses of IL-12 for in-vivo proliferation of hematopoietic repopulating cells, hematopoietic progenitor cells and hematopoietic stem cells. Other disclosed methods are directed to uses of IL-12 for bone marrow preservation or recovery. | 2011-08-25 |
20110206636 | Use of Endoperoxides for the Treatment of Infections Caused by Flaviviridae, Including Hepatitis C, Bovine Viral Diarrhea and Classical Swine Fever Virus - The use of sesquiterpenes and, in particular sesquiterpene lactone endoperoxides, such as artemisinin and analogs thereof, for the treatment of hepatitis C virus infections. Artemisinin, analogs of artemsisnin and some crude | 2011-08-25 |
20110206637 | ANTIVIRAL AGENTS - The present invention provides antiviral compounds of formula (I), | 2011-08-25 |
20110206638 | COMPOSITIONS AND METHODS FOR REDUCING THE MUTATION RATE OF VIRUSES - The disclosure provides compositions and methods for reducing the mutation rate of a virus, such as an RNA virus or a DNA virus, in a cell infected with the virus by, in one aspect, contacting the cell with an effective amount of an iron chelator or an antioxidant. Also provided are compositions and methods for enhancing the efficacy of an agent or a therapy directed at a virus. | 2011-08-25 |
20110206639 | REPLICATION COMPETENT VIRUSES CAPABLE OF SILENCING VIRUS INHIBITORY FACTOR EXPRESSION - Described is a replication competent virus, being capable to replicate and having lytic capacity in host cells, the virus comprising in the genome thereof, at least one DNA sequence coding for a silencing factor functional in reducing expression of a target gene in the said host cells, operably linked to one or more expression control sequences, functional in the said host cells, and the use thereof in the preparation of a medicament and to the use thereof in a method for lysing host cells expressing a virus inhibitory factor. | 2011-08-25 |
20110206640 | ENGINEERED SYNERGISTIC ONCOLYTIC VIRAL SYMBIOSIS - In one aspect, the invention provides methods for preferentially killing target proliferating cells in a host, such as cancer cells, by infecting host tissues with two or more strains of virus. The strains of virus may be selected to provide a synergistic and symbiotic effect, involving a contemporaneous lytic infection in the target proliferating cells. In selected embodiments, the viruses are selected so that expression of a first virulence factor in proliferating cells infected with the first virus increases the lytic effect of the second virus; and, expression of the second virulence factor in proliferating cells infected with the second virus increases the lytic effect of the first virus. The genomes of the first and second viruses may be selected so that they are incompatible for recombination between the viral genomes in cells of the host. | 2011-08-25 |
20110206641 | STRESS TOLERANT BIFIDOBACTERIA - The present invention relates in general to the field of Bifidobacteria. In particular the present invention relates to the field of Bifidobacteria with a modulated stress resistance. One embodiment of the present invention is a | 2011-08-25 |
20110206642 | Preventing obesity-related metabolic syndrome with melagonesis - Anti-inflammatory effect of α-MSH-like compounds can be employed for curtailing sequelae of obesity and overweight. Importantly, molecular compounds that stimulate melanin biosynthesis by mimicking the effects of α-MSH are readily available for trials aimed at control of metabolic syndrome components. Synthetic agonists of α-MSH receptors, melanotan II and bremelanotide, have already been proven safe in human trials for therapeutic tanning and some non-obesity-related diseases. | 2011-08-25 |
20110206643 | Automated Cell Therapy System - A method for automated cell processing is provided, including receiving at least one tissue containing a multiplicity of cells belonging to multiple cell types, and automatically increasing both the proportion of cells of at least one of said multiple cell types as compared with at least another of said multiple cell types and the absolute number of cells of said at least one of said multiple cell types. Other embodiments are also described. | 2011-08-25 |
20110206644 | METHODS FOR TRANS-DIFFERENTIATING CELLS - The present provides methods for affecting and/or altering the differentiation state of a cell. In certain embodiments, the present invention provides methods to transdifferentiate a cell into an endothelial cell or a hematopoietic cell. In the practice of the invention, a demethylating agent (e.g., 5-azacytidine) is used to affect and/or alter the differentiation state of a cell. The invention demonstrates the transdifferentiation of numerous cell types, including cell populations that are themselves somewhat differentiated (e.g., normal fibroblasts) into distinct cell types, including hematopoietic cells and endothelial cells, which transdifferentiation is effected further through the selection of particular growth factors which, together with the demethylating agents, directs the differentiation path. The invention provides a novel approach to providing useful cell types for many types of medical applications. | 2011-08-25 |
20110206645 | TREATMENT OF BONE-RELATED CANCERS USING PLACENTAL STEM CELLS - Provided herein are methods of suppression of proliferation and growth of cells of bone-related cancers, e.g., multiple myeloma or chondrosarcoma cells, using placental cells, e.g., the placental stem cells described herein, and populations of such placental cells. Also provided herein are methods of treating individuals having cells of a bone-related cancer. | 2011-08-25 |
20110206646 | METHODS OF USING ADIPOSE TISSUE-DERIVED CELLS IN THE TREATMENT OF THE LYMPHATIC SYSTEM AND MALIGNANT DISEASE - Aspects of the invention provides methods for preparing and using adipose-tissue-derived stem and progenitor cells, adipose-tissue-derived lymphatic endothelial cells, and cells capable of differentiating into lymphatic endothelial cells to treat disorders of the lymphatic system and to modulate expansion, repair, and/or regeneration of the lymphatic system. The invention further provides using adipose-tissue-derived lymphatic endothelial cells and cells capable of differentiating into lymphatic endothelial cells for delivery of therapeutic agents to tumor cells as a means for treating malignant disease, and assays to screen for drugs that modulate lymphatic system expansion, repair or regeneration. | 2011-08-25 |
20110206647 | Modulation of Angiogenesis - The invention provides methods for treating pathological conditions that can be improved by providing angiogenesis. The invention is generally directed to provide angiogenesis by administering cells that express and/or secrete one or more pro-angiogenic factors. The invention is also directed to drug discovery methods to screen for agents that modulate the ability of the cells to express and/or secrete one or more pro-angiogenic factors. The invention is also directed to cell banks that can be used to provide cells for administration to a subject, the banks comprising cells having desired levels of expression and/or secretion of one or more pro-angiogenic factors. | 2011-08-25 |
20110206648 | Gene-enhanced tissue engineering - Provided are mammalian cells comprising a recombinant sonic hedgehog (SHH) gene such that a recombinant SHH protein can be expressed by the cell. Also provided are matrices suitable for applying to a tissue defect. Additionally provided are tissue regeneration compositions. Methods of regenerating tissue at the site of a tissue defect in a mammal are also provided. | 2011-08-25 |
20110206649 | NUTRITIONAL COMPOSITION COMPRISING PROBIOTICS AND IMPROVING SLEEP PATTERNS - This invention relates to the use of a probiotic bacterial strain in the manufacture of a medicament or therapeutic nutritional composition for improving the maturation of sleep patterns in infants, young children or young animals and/or for reducing sleep disturbances and/or improving sleep patterns in humans or animals at any age. | 2011-08-25 |
20110206650 | Probiotic Formulations - The present invention relates to probiotic compositions and kits thereof, comprising live bacteria belonging to the natural flora of the human body cavity such as intestine and vaginal tract, in particular, strains of | 2011-08-25 |
20110206651 | FACTOR VIII POLYMER CONJUGATES - The invention is a proteinaceous construct comprising a Factor VIII molecule which is conjugated to a water-soluble polymer via carbohydrate moieties of Factor VIII, and methods of preparing same. | 2011-08-25 |
20110206652 | METHODS FOR TREATING ATHEROSCLEROSIS - The invention provides compounds, pharmaceutical compositions and methods for treating atherosclerosis, inflammation, thrombosis and other conditions and for decreasing or prevention of accumulation of cholesterol in a subject by modifying LCAT polypeptide. | 2011-08-25 |
20110206653 | TETRAZOLE COMPOUNDS FOR REDUCING URIC ACID - Uric acid in mammalian subjects is reduced and excretion of uric acid is increased by administering a compound of Formula I. The uric acid-lowering effects of the compounds of this invention are used to treat or prevent a variety of conditions including gout, hyperuricemia, elevated levels of uric acid that do not meet the levels customarily justifying a diagnosis of hyperuricemia, renal dysfunction, kidney stones, cardiovascular disease, risk for developing cardiovascular disease, tumor-lysis syndrome, cognitive impairment, early-onset essential hypertension, and | 2011-08-25 |
20110206654 | Methods of Modulating Gastrointestinal Tract Flora Levels with Alkaline Phosphatase - This invention relates generally to a therapeutic use of alkaline phosphatase to modulate gastrointestinal tract flora levels in subject. | 2011-08-25 |
20110206655 | FVIII-INDEPENDENT FIX-MUTANT PROTEINS FOR HEMOPHILIA A TREATMENT - The present invention relates to recombinant blood coagulation factor IX (rFIX) mutants having factor VIII (FVIII) independent factor X (FX) activation potential. Five full length FIX proteins with combinations of mutations of amino acids important for functional activity of FIX and FIX wild type were cloned and expressed in HEK 293 cells. The proteins were tested by an activated partial thromboplastin time (aPTT) assay in FVIII-depleted plasma as well as in FVIII-inhibited patient plasma. In FVIII-depleted plasma functional activity of the FIX mutants was calculated as increased FVIII equivalent activity. The mutant proteins had increased FVIII equivalent activity. In FVIII-inhibited patient plasma the FEIBA equivalent activity was calculated for analysis of FVIII independent FX activation potential. The proteins had also increased FEIBA equivalent activity. Furthermore, the pre-activated FIX proteins had an increased activity in FIX-depleted plasma containing FVIII inhibitors. Therefore these FIX mutants are alternatives as bypassing agents for treatment of FVIII inhibitor patients. | 2011-08-25 |
20110206656 | EMERGENCY INTERVENTIONS OF ACTIVE CHARCOAL WITH DABIGATRAN ETEXILATE OVERDOSING - The invention relates to a method for treating an overdosing with active substance dabigatran etexilate of formula I | 2011-08-25 |
20110206657 | ANTIBODIES BINDING TO AN INTRACELLULAR PRL-1 OR PRL-3 POLYPEPTIDE - We provide an antibody capable of | 2011-08-25 |
20110206658 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF TUMOR OF HEMATOPOIETIC ORIGIN - The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals and to methods of using those compositions of matter for the same. | 2011-08-25 |
20110206659 | METHODS AND TREATMENT FOR ALLERGIES AND INFLAMMATION ASSOCIATED WITH GASTROINTESTINAL DISEASES - Methods of the prophylaxis of the development of allergy in a patient at risk of sensitization to an antigen(s) or allergen(s) due to impaired gastrointestinal functions include administering a mast cell inhibitor, e.g., ketotifen, e.g., ketotifen fumarate. Methods for prophylactically treating, reducing, delaying or controlling gastrointestinal disorders include administering a mast cell stabilizer, e.g., ketotifen to a patient in need thereof. Pharmaceutical preparation, composition for use in methods described, are also disclosed. Also disclosed are methods of prophylaxis or treating gastrointestinal and esophageal inflammation, and methods for the prophylaxis of the development of additional allergies to a newly introduced substance in a patient with a preexisting allergy. Such methods include delivery of a mast cell stabilizer, e.g., ketotifen. Oral and topical administration are contemplated within the scope of the methods. | 2011-08-25 |
20110206660 | AMINO ACID SEQUENCES DIRECTED AGAINST CXCR4 AND OTHER GPCRS AND COMPOUNDS COMPRISING THE SAME - The present invention relates to amino acid sequences that are directed against (as defined herein) G-protein coupled receptors (GPCRs) and in particular to CXCR4 and CXCR7, as well as to compounds or constructs, and in particular proteins and polypeptides, that comprise or essentially consist of one or more such amino acid sequences (also referred to herein as “amino acid sequences of the invention”, “compounds of the invention”, and “polypeptides of the invention”, respectively). Furthermore, the invention provides a new method of making amino acid sequences that are directed against transmembrane protein, and in particular for multiple spanning transmembrane proteins for which the native conformation cannot be reproduced in other “in vitro” system (e.g. GPCRs in general). | 2011-08-25 |
20110206661 | TRIMETHOXYPHENYL INHIBITORS OF TYROSINE KINASE - The present invention relates to new trimethoxyphenyl inhibitors of tyrosine kinase, pharmaceutical compositions thereof, and methods of use thereof. | 2011-08-25 |
20110206662 | ANTI-ANGIOGENESIS THERAPY FOR THE TREATMENT OF OVARIAN CANCER - This invention concerns in general treatment of diseases and pathological conditions with anti-VEGF antibodies. More specifically, the invention concerns the treatment of human patients susceptible to or diagnosed with cancer using an anti-VEGF antibody, preferably in combination with one or more additional anti-tumor therapeutic agents for the treatment of ovarian cancer. | 2011-08-25 |
20110206663 | Anti-Interferon-Alpha Antibodies - The present invention relates generally to the generation and characterization of neutralizing anti-IFN-α monoclonal antibodies with broad reactivity against various IFN-α subtypes. The invention further relates to the use of such anti-IFN-α antibodies in the diagnosis and treatment of disorders associated with increased expression of IFN-α, in particular, autoimmune disorders such as insulin-dependent diabetes mellitus (IDDM) and systemic lupus erythematosus (SLE). | 2011-08-25 |
20110206664 | Therapeutic agent for chronic arthritides diseases of childhood-related diseases - A therapeutic agent for chronic arthritides diseases of childhood-related diseases, for example chronic arthritides diseases of childhood, Still's disease and the like, comprising an interleukin-6 (IL-6) antagonist as an active ingredient. | 2011-08-25 |
20110206665 | TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER - The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. | 2011-08-25 |
20110206666 | TARGETING PAX2 FOR THE TREATMENT OF BREAST CANCER - The present application provides methods of prevention and/or treatment of breast cancer in a subject by inhibiting expression of PAX2. In the cancer treatment methods disclosed, the method of inhibiting expression of PAX2 can be by administration of a nucleic acid encoding an siRNA for PAX2. A method of treating cancer in a subject by administering DEFB1 is also provided. Similarly, provided is a method of treating cancer in a subject by increasing expression of DEFB1 in the subject. | 2011-08-25 |
20110206667 | POLYMORPHISM IN THE APO(A) GENE PREDICT RESPONSIVENESS TO ACETYLSALICYLIC ACID TREATMENT - This invention relates to nucleotide polymorphisms in the human Apo(a) gene and to the use of Apo(a) nucleotide polymorphisms in identifying whether a human subject will respond or not to treatment with acetylsalicylic acid. | 2011-08-25 |
20110206668 | METHODS AND COMPOSITIONS FOR MODULATING IMMUNITY - Methods and compositions for inducing immune suppression are disclosed. The methods involve administering an effective amount of a CD200 protein or a nucleic acid encoding a CD200 protein. The methods are useful in preventing graft rejection, fetal loss, autoimmune disease, and allergies. Methods and compositions for preventing immune suppression are also disclosed. The methods involve administering an effective amount of an agent that inhibits CD200. Such methods are useful in treating cancer. | 2011-08-25 |
20110206669 | MCP1 FUSIONS - The present invention provides polypeptides including MCP1 fused, optionally, by a linker, to an immunoglobulin. Methods for using the polypeptides to treat medical disorders are also covered. | 2011-08-25 |
20110206670 | METHODS AND MATERIALS RELATED TO ANTI-AMYLOID ANTIBODIES - This document provides methods and materials related to anti-amyloid antibodies. For example, anti-amyloid antibodies, methods for making anti-amyloid antibodies, and methods for using an anti-amyloid antibody to treat or prevent an amyloid condition (e.g., AD) are provided. | 2011-08-25 |
20110206671 | AXON REGENERATION PROMOTER - An axon regeneration promoter is disclosed that contains an inhibitor of RGM-like protein as an effective component. Inhibitors of RGM-like protein encompass inhibitors of RGM-like protein such as anti-RGM-like protein antibodies and Y27632, as well as antisense nucleic acids and double-stranded RNAs that can inhibit the transcription or translation of RGM-like protein. The axon regeneration promoter according to the present invention is effective for the regeneration of central nerve axons and thus contributes, for example, to the treatment of patients who have suffered damage to the central nervous system, for example, the spinal cord, due to, for example, a traffic accident or a cerebrovascular disorder. | 2011-08-25 |
20110206672 | Antigen-Binding Molecule And Uses Thereof - In one aspect, the present invention relates to an antigen-binding molecule specific for albumin and CD3 which may comprise two polypeptide chains, each polypeptide chain having at least four variable domains in an orientation preventing Fv formation and the two polypeptide chains are dimerized with one another thereby forming a multivalent antigen-binding molecule. On each of the two polypeptide chains the four variable domains may be arranged in the order V | 2011-08-25 |
20110206673 | POLYPEPTIDES AND POLYNUCLEOTIDES FOR ARTEMIN AND RELATED LIGANDS, AND METHODS OF USE THEREOF - The invention encompasses polypeptides, polynucleotides, and antibodies, for Artemin and related ligands, including Persephin (PSPN). The invention also encompasses expression vectors and host cells for producing these polypeptides, polynucleotides, or antibodies. The invention further encompasses diagnostics and therapeutics, especially for cancer, and particularly breast cancer, colon cancer, prostate cancer, endometrial cancer, lung cancer, stomach cancer, liver cancer, and others, comprising one or more of the disclosed polypeptides, polynucleotides, antibodies, expression vectors, host cells, or compositions thereof. Particularly encompassed are inhibitors of Artemin and/or related ligands, and uses for these inhibitors. | 2011-08-25 |
20110206674 | Yersinia SPP. Polypeptides and Methods of Use - The present invention provides isolated polypeptides isolatable from a | 2011-08-25 |
20110206675 | ANTI-NOTCH3 AGONIST ANTIBODIES AND THEIR USE IN THE TREATMENT OF NOTCH3-RELATED DISEASES - The present invention relates to agonist antibodies that specifically bind to Notch 3 and activate signaling. The present invention includes antibodies binding to an epitope comprising the first Lin12 domain. The present invention also includes uses of these antibodies to treat or prevent Notch 3 related diseases or disorders. | 2011-08-25 |
20110206676 | COMPOSITIONS AND METHODS RELATED TO STAPHYLOCOCCAL BACTERIUM PROTEINS - The present invention concerns methods and compositions for treating or preventing a bacterial infection, particularly infection by a | 2011-08-25 |
20110206677 | ANTIBODIES SPECIFIC FOR SCLEROSTIN AND METHODS FOR INCREASING BONE MINERALIZATION - Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures. | 2011-08-25 |
20110206678 | Antibodies Specific for Sclerostin and Methods for Increasing Bone Mineralization - Compositions and methods relating to antibodies that specifically bind to TGF-beta binding proteins are provided. These methods and compositions relate to altering bone mineral density by interfering with the interaction between a TGF-beta binding protein sclerostin and a TGF-beta superfamily member, particularly a bone morphogenic protein. Increasing bone mineral density has uses in diseases and conditions in which low bone mineral density typifies the condition, such as osteopenia, osteoporosis, and bone fractures. | 2011-08-25 |
20110206679 | New Therapeutic and Diagnostic Methods for Alzheimer's Disease - The invention relates to diagnosing the presence or absence of antibodies, such as IgM, IgG or IgA antibodies, related to increased or decreased risk of developing Alzheimer's disease, using a phosphorylcholine conjugate. In addition, the invention relates to methods of immunization and prophylaxis, prevention and/or treatment of a subject against Alzheimer's disease, the method comprising the step of administering to the subject a pharmaceutical composition comprising at least one phosphoryl-choline conjugate, or the step of administering to the subject an antibody preparation, for example a monoclonal antibody, with reactivity to a phosphorylcholine and/or a conjugate thereof. | 2011-08-25 |
20110206680 | METHODS FOR TREATING PSORIASIS - The invention provides methods of treating psoriasis in a subject by administering to a subject an antibody capable of binding to the p40 subunit of IL-12 and/or IL-23. | 2011-08-25 |
20110206681 | BINDING MOLECULES TO THE HUMAN OX40 RECEPTOR - The present disclosure provides isolated binding molecules that bind to the human OX40R, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions. | 2011-08-25 |
20110206682 | MONOCLONAL ANTIBODIES, SYNTHETIC AND BIOTECHNOLOGICAL DERIVATIVES THEREOF ACTING AS NGF-ANTAGONIST MOLECULES - Monoclonal antibodies, synthetic and biotechnological derivatives thereof (ScFv or others) are able to recognise the NGF high affinity receptor, TrkA, and act as NGF-antagonist molecules. Pharmacological compositions for therapy, gene therapy, diagnostics of neurological pathologies are also described. Transgenic animal models to study such pathologies are also described. | 2011-08-25 |
20110206683 | PRESERVATION MIXTURE AND USE THEREOF - The invention relates to a preservation composition, a formulation comprising a preservation mixture of glutamate, a saccharide, and a polymer. Said preservation mixture is advantageously used for the preservation of a biological compound. | 2011-08-25 |
20110206684 | METHOD OF PRODUCING NUTRITIONAL PRODUCTS FROM HUMAN MILK TISSUE AND COMPOSITIONS THEREOF - Methods of isolating, treating, storing and processing human milk, as well as nutritional formulations of human milk comprising protective human milk proteins. | 2011-08-25 |
20110206685 | SCREENING ASSAYS FOR INHIBITORS OF A STAPHYLOCOCCUS AUREUS SIDEROPHORE - Isolation of an iron regulated, nme-gene operon (designated sbn) from | 2011-08-25 |
20110206686 | IL-23 ANTIBODIES - The present invention relates to antigen binding proteins to human IL-23, pharmaceutical formulations containing them and to the use of such antigen binding proteins in the treatment and/or prophylaxis of inflammatory diseases such as Rheumatoid Arthritis (RA). | 2011-08-25 |
20110206687 | Isolation And Purification Of Anti-IL-13 Antibodies Using Protein A Affinity Chromatography - Disclosed herein are methods for the isolation and purification of anti-IL-13 antibodies wherein the use of an affinity chromatographic step results in an antibody composition sufficiently pure for pharmaceutical uses. The methods described herein comprise pH viral reduction/inactivation, ultrafiltration/diafiltration, affinity chromatography (e.g., Protein A affinity chromatography), ion exchange chromatography, and hydrophobic chromatography. Further, the present invention is directed toward pharmaceutical compositions comprising one or more antibodies of the present invention. | 2011-08-25 |
20110206688 | Enhancing Vessel Lesion Homing and Repair Potential of Stem Cells - Disclosed herein are methods of enhancing repair of vascular lesions involving the administration of cells in which TGF-β expression and/or activity has been transiently blocked. Other methods involve the administration of a TGF-β blocking agent to a subject who has a vascular lesion or is at risk of developing a vascular lesion. Alternatively, a TGF-β blocking agent and treated cells are co-administered to a subject in need thereof. | 2011-08-25 |
20110206689 | Molecular Determinants Associated With Prostate Cancer And Methods Of Use Thereof - The present invention provides methods of treating cancer by inhibiting pserine threonine kinase activity and detecting cancer using biomarkers. | 2011-08-25 |
20110206690 | DIMERIC IAP INHIBITORS - The present invention provides compounds of formula M-L-M′ (where M and M′ are each independently a monomeric moiety of Formula (I) and L is a linker). The dimeric compounds have been found to be effective in promoting apoptosis in rapidly dividing cells. | 2011-08-25 |
20110206691 | Methods and Compositions for Treating Neuroblastoma - Methods and compositions for treating neuroblastoma are disclosed. | 2011-08-25 |
20110206692 | CONFORMERS OF BACTERIAL ADHESINS - The invention relates to isolated or purified bacterial adhesin conformers, preferably with improved stability and/or immunogenicity. In a preferred aspect, the invention comprises an isolated bacterial adhesin conformer F. Also provided are methods of isolation and/or separation of such adhesin conformers. The compositions may include one or more of the immunogenic polypeptides either alone or with other antigenic components. For example, the immunogenic polypeptides may be combined with other bacterial antigens to provide therapeutic compositions with broader range. | 2011-08-25 |
20110206693 | LYSINE RIBOSWITCH AND COMPOSITIONS AND USES THEREOF - Embodiments herein provide for lysine riboswitches and analogs thereof, and methods for using the same. In certain embodiments, test compounds are identified that associate with lysine riboswitches. In other embodiments, test compounds found to associate with lysine can be used to increase or decrease gene expression of Gram-negative bacterial organisms. | 2011-08-25 |
20110206694 | Prevention and treatment of gram negative, flagellated bacterial infections - The present invention describes a novel mechanism of adhesion by flagellated Gram-negative bacteria such as enterotoxigenic | 2011-08-25 |
20110206695 | ANTIBODIES FOR DIAGNOSIS AND THERAPEUTIC TREATMENT OF PROSTATE CANCER - XMRV appears to be related to both prostate cancer if it infects a male germ cell and chronic fatigue syndrome in both sexes. (If the virus does not infect a germ cell). Prostate cancer cells exhibit TSG101 on the surface only upon infection with a virus like XMRV. Antibodies to TSG101 can be effective diagnostics to identify individuals with a predisposition to prostate. They can also be used in place of current diagnostics to confirm the presence of prostate cancer. TSG101 antibodies, when administered in vivo, exhibit the ability to reduce tumor size, suppress metastatic transformation and extend survival. | 2011-08-25 |
20110206696 | METHODS FOR INHIBITING BONE LOSS AND BONE METASTASIS - The invention encompasses methods of inhibiting bone loss and bone metastasis. | 2011-08-25 |
20110206697 | SPINK1 TARGETED THERAPY - The present invention relates to compositions and methods for cancer therapy, including but not limited to, targeted inhibition of cancer markers. In particular, the present invention relates to SPINK1 as a clinical target for prostate cancer. | 2011-08-25 |
20110206698 | ANTAGONIST ANTI-IL-7 RECEPTOR ANTIBODIES AND METHODS - The present invention provides antagonizing antibodies that bind to interleukin-7 receptor (IL-7R). The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acids. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof for the treatment and/or prevention of type 2 diabetes and immunological disorders, including type 1 diabetes, multiple sclerosis, rheumatoid arthritis, graft-versus-host disease, and lupus. | 2011-08-25 |
20110206699 | Methods for the Treatment of Graft-Versus-Host Disease - Methods are disclosed for treating or preventing graft versus host disease in a subject. The methods include selecting a subject in need of treatment for graft versus host disease; and administering to the subject a therapeutically effective amount of a TLR5 agonist such as a flagellin polypeptide, or a polynucleotide encoding the flagellin, thereby treating or preventing graft versus host disease in the subject. Methods are also disclosed for reducing susceptibility to an opportunistic infection in a subject who is a bone marrow transplant recipient. The methods include selecting a subject who has had a bone marrow or hematopoietic stem cell transplant; and administering to the subject a therapeutically effective amount of a TLR5 agonist such as a flagellin polypeptide or a polynucleotide encoding the polypeptide, and administering to the subject an effective amount antigen of the opportunistic infection, thereby reducing the susceptibility to the opportunistic infection in the subject. | 2011-08-25 |
20110206700 | ANTI-CD33 ANTIBODIES AND METHODS FOR TREATMENT OF ACUTE MYELOID LEUKEMIA USING THE SAME - The present invention relates to antibodies that bind CD33. More particularly, the invention relates to anti-CD33 antibodies, fragments and homologues of these antibodies, humanized and resurfaced versions of these antibodies, functional equivalents and improved versions of these antibodies, immunoconjugates and compositions comprising these antibodies, and the uses of same in diagnostic, research and therapeutic applications. The invention also relates to a polynucleotide encoding these antibodies, vectors comprising the polynucleotides, host cells transformed with polynucleotides and methods of producing these antibodies. | 2011-08-25 |
20110206701 | USE OF ANTI-CS1 ANTIBODIES FOR TREATMENT OF RARE LYMPHOMAS - Uses of anti-CS1 antibodies, alone or in combination with other agents, for the treatment of rare lymphomas, such as NK lymphomas, NK/T-cell lymphomas, and angioimmunoblastic lymphomas. | 2011-08-25 |
20110206702 | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS AND TREATMENT OF TUMOR - The present invention is directed to compositions of matter useful for the diagnosis and treatment of tumor in mammals and to methods of using those compositions of matter for the same. | 2011-08-25 |
20110206703 | GENE SIGNATURE FOR PREDICTING PROGNOSIS OF PATIENTS WITH SOLID TUMORS - Disclosed herein is a driver gene signature for predicting survival in patients with solid tumors, such as hepatocellular carcinoma (HCC) and breast cancer. The gene signature includes ten tumor-associated genes, SH2D4A, CCDC25, ELP3, DLC1, PROSC, SORBS3, HNRPD, PAQR3, PHF17 and DCK. A decrease in DNA copy number or mRNA expression of SH2D4A, CCDC25, ELP3, DLC1, PROSC and SORBS3 in solid tumors is associated with a poor prognosis, while a decrease in DNA copy number or mRNA expression of HNRPD, PAQR3, PHF17 and DCK in solid tumors is associated with a good prognosis. Thus, provided herein is a method of predicting the prognosis of a patient diagnosed with HCC or breast cancer by detecting expression of one of more tumor-associated genes in a tumor sample and comparing expression of the one or more tumor-associated genes in the tumor sample to a control. Also provided is a method of treating a patient diagnosed with HCC or breast cancer by administering a therapeutically effective amount of an agent that alters expression or activity of one or more of the disclosed tumor-associated genes. Further provided are arrays comprising probes or antibodies specific for a plurality of tumor-associated genes or proteins. | 2011-08-25 |
20110206704 | Methods and compositions for modulating hepatocyte growth factor activator - The present invention relates generally to the fields of molecular biology and growth factor regulation. More specifically, the invention concerns modulators of hepatocyte growth factor activator function, and the identification and uses of said modulators. | 2011-08-25 |
20110206705 | B7-H3 AS A BIOMARKER FOR DIAGNOSING THE PROGRESSION AND EARLY LYMPH NODE METASTASIS OF CANCER - B7H3 is a ligand member of the immunoregulatory family of proteins on immune cells. In one embodiment, a method for diagnosing the progression of cancer with a high propensity of primary tumor metastasis to the lymph node or distant site is provided. Such a method may comprise obtaining a cancer tissue sample from a cancer patient, determining an expression level of B7-H3 present in the tissue sample, and diagnosing the progression of the cancer having a high propensity of primary tumor metastasis to the lymph node or distant site based upon the expression level, wherein an increased expression level correlates with an increased probability of having regional lymph nodes or organ site that are positive for metastases. | 2011-08-25 |
20110206706 | VACCINE AND METHOD FOR TREATMENT OF NEURODEGENERATIVE DISEASES - Methods and compositions are provided for treatment of neurodegenerative diseases in which there is accumulation of misfolded and/or aggregated proteins, excluding prion diseases. In particular, the invention relates to treatment of the neurodegenerative diseases Huntington's disease (HD), Alzheimer's disease (AD) or Parkinson's disease (PD), by administration of an agent selected from the group consisting of (i) Copolymer 1, (ii) a Copolymer 1-related peptide, (iii) a Copolymer 1-related polypeptide, and (iv) T cells activated with (i), (ii) or (iii). | 2011-08-25 |
20110206707 | Method for stimulating a host immune system - A method of manipulating allogeneic cells for use in allogeneic cell therapy protocols is described. The method provides a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune mechanism called the “Mirror Effect”. In contrast to current allogeneic cell therapy protocols where T-cells in the graft mediate the beneficial graft vs. tumor (GVT) and detrimental graft vs. host (GVH) effects, the allogeneic cells of the present invention stimulate host T-cells to mediate the “mirror” of these effects. The mirror of the GVT effect is the host vs. tumor (HVT) effect. The “mirror” of the GVH effect is the host vs. graft (HVG) effect. The effectiveness and widespread application of the anti-tumor GVT effect is limited by the severe toxicity of the GVH effect. In the present invention, the anti-tumor HVT effect occurs in conjunction with a non-toxic HVG rejection effect. The highly activated allogeneic cells of the invention can be used in methods to stimulate host immunity. The method includes a complete HLA mis-matched setting in patients that have not had a prior bone marrow transplant or received chemotherapy and/or radiation conditioning regimens. | 2011-08-25 |
20110206708 | Method for stimulating a therapeutic immune effect in a patient - A method of manipulating allogeneic cells for use in allogeneic cell therapy protocols is described. The method provides a composition of highly activated allogeneic T-cells which are infused into immunocompetent cancer patients to elicit a novel anti-tumor immune mechanism called the “Mirror Effect”. In contrast to current allogeneic cell therapy protocols where T-cells in the graft mediate the beneficial graft vs. tumor (GVT) and detrimental graft vs. host (GVH) effects, the allogeneic cells of the present invention stimulate host T-cells to mediate the “mirror” of these effects. The mirror of the GVT effect is the host vs. tumor (HVT) effect. The “mirror” of the GVH effect is the host vs. graft (HVG) effect. The effectiveness and widespread application of the anti-tumor GVT effect is limited by the severe toxicity of the GVH effect. In the present invention, the anti-tumor HVT effect occurs in conjunction with a non-toxic HVG rejection effect. The highly activated allogeneic cells of the invention can be used to stimulate host immunity in a complete HLA mis-matched setting in patients that have not had a prior bone marrow transplant or received chemotherapy and/or radiation conditioning regimens. | 2011-08-25 |
20110206709 | T-CELL ANTIGEN PEPTIDE FROM ALLERGEN FOR STIMULATION OF IL-10 PRODUCTION - A first or second polypeptide for use in a method of treating or preventing a disorder by tolerisation, wherein said method comprises administration of the first and second polypeptide; and wherein both first and second polypeptides: i) are of 7 to 30 amino acids in length; ii) comprise at least one MHC Class Il-binding T cell epitope; and iii) are a fragment of a protein allergen or a homologous variant of said fragment; wherein said first polypeptide induces the release of an amount of IL-10 that is greater than the amount of IL-10 released in response to the whole protein allergen from which the first polypeptide derives; wherein said disorder is characterised by an inappropriate immune response to the protein allergen from which the second polypeptide derives. | 2011-08-25 |
20110206710 | Recombinant lentiviral vector for expression of a flaviviridae protein and applications thereof as a vaccine - Use of a recombinant lentiviral vector comprising a polynucleotide fragment encoding at least one protein of a virus of the family Flaviviridae or an immunogenic peptide of at least 8 amino acids of said protein, for preparing a pharmaceutical composition intended for the prevention and/or the treatment of a Flaviviridae infection in a sensitive species. | 2011-08-25 |
20110206711 | METHOD FOR INDUCING CYTOTOXIC T-CELLS, CYTOTOXIC T-CELL INDUCER, AND PHARMACEUTICAL COMPOSITION AND VACCINE EMPLOYING SAME - A method for inducing cytotoxic T-cells that includes binding to an HLA molecule on the surface of a cell that is a target of a cytotoxic T-cell a peptide containing one or more types of amino acid sequence selected from the group consisting of SEQ ID NOS: 1 to 13 and consisting of not less than 8 and not more than 11 amino acid residues, or a peptide derived from a precursor thereof. | 2011-08-25 |
20110206712 | TUBERCULOSIS RV2386C PROTEIN, COMPOSITIONS AND USES THEREOF - The present invention is directed to a polypeptide which comprises: (i) an Rv2386c protein sequence; (ii) a variant of an Rv2386c protein sequence; or (iii) an immunogenic fragment of an Rv2386c protein sequence. In other aspects the invention is directed to associated polynucleotides, fusion proteins and methods for the treatment or prevention of tuberculosis. | 2011-08-25 |
20110206713 | TUBERCULOSIS VACCINES COMPRISING ANTIGENS EXPRESSED DURING THE LATENT INFECTION PHASE - The invention is related to an immunogenic composition, vaccine or pharmaceutical composition for preventing, boosting or treating infection caused by a species of the | 2011-08-25 |
20110206714 | MALARIA VACCINE COMPOSITIONS AND CONSTITUENTS WHICH ELICIT CELL MEDIATED IMMUNITY - Malaria vaccines based on polyepitope constructs that elicit cell-mediated immunity against a broad spectrum of malaria parasites and which cover the majority of HLA alleles are provided. Epitopes in the polyepitope constructs are from regions of the | 2011-08-25 |
20110206715 | MOLECULAR DIFFERENCES BETWEEN SPECIES OF THE M. TUBERCULOSIS COMPLEX - Specific genetic deletion are identified in mycobacteria isolates, including variations in the | 2011-08-25 |
20110206716 | SYNERGISTIC IMMUNOGENIC FUSION PROTEIN-POLYSACCHARIDE CONJUGATE - An immunogenic composition comprising a fusion protein-polysaccharide conjugate consisting of a polysaccharide (PS) or pneumococcal bacterial cell wall polysaccharide (CWPS) conjugated to X:PdT where PdT represents the nonhemolytic variant of pneumolysin and X represents an antigenic peptide or protein of interest is provided. The immunity to X is synergistically enhanced by the fusion conjugate. Methods of protecting a subject from pneumococcal colonization or disease by administering an immunogenic composition including a fusion protein (PsaA:PdT) containing truncated PsaA and the nonhemolytic variant of pneumolysin (PdT) conjugated with CWPS (PsaA:PdT-CWPS) is also provided. | 2011-08-25 |
20110206717 | NON-TYPHOIDAL SALMONELLA VACCINES - OmpD of non-typhoidal | 2011-08-25 |
20110206718 | ANTI-FMD VACCINE COMPOSITION AND PREPARATION AND USE THEREOF - The present invention pertains to the field of immunology and genetic engineering. In particular, the present invention relates to the construction, preparation and use of a recombinant vaccine against foot-and-mouth disease virus. The vaccine comprises a tandem repeat of an antigenic epitope of FMDV VP1 protein, the constant region of the immunoglobulin heavy chain or a functional fragment thereof, and the FMDV 3D protein or an immunogenic fragment thereof. The vaccine can induce protective immune response against FMDV in an animal. | 2011-08-25 |
20110206719 | IMMUNOSTIMULATORY OLIGORIBONUCLEOTIDES - The invention provides immunostimulatory compositions and use of those compounds in the preparation of medicaments for the treatment of disease as well as in vitro uses. In particular, the compositions of the invention include immunostimulatory oligoribonucleotides that incorporate a sequence-dependent immunostimulatory sequence motif. Specific modifications involving phosphate linkages, nucleotide analogs, adducts, and combinations thereof are provided. Compositions of the invention, which optionally can include an antigen, can be used alone or together with other treatments to stimulate or enhance an immune response. Also provided are compositions and methods useful for treating a subject having an infection, a cancer, an allergic condition, asthma, airway remodeling, or immunodeficiency. Immunostimulatory oligoribonucleotides of the invention are believed to stimulate Toll-like receptor 8 (TLR8). | 2011-08-25 |
20110206720 | ANTI-INFLAMMATORY USAGE OF ANTRODIA CINNAMOMEA FRUIT BODY DERIVATIVES - The present invention is related to the usage of | 2011-08-25 |
20110206721 | FERMENTED SOY NUTRITIONAL SUPPLEMENTS INCLUDING MUSHROOM COMPONENTS - Dietary, health, and/or nutritional supplements provide various formulations of mushrooms grown in fermented soy, with or without rice flour, optionally in combination with sweetener(s), curcumin, and various other herbs and spices. Certain embodiments or compositions may be in liquid, beverage, solid, paste or powder forms. In certain embodiments the supplements contain mushroom species grown in fermented soy in the presence of certain bacterial species and optionally rice or rice flour. In some embodiments, other ingredients that may be present include one or more of curcumin, desmethoxycurcumin and bis-desmethoxycurcumin or all three curcumins. Certain embodiments may be used to treat or provide symptomatic relief from a variety of maladies ranging from malnutrition to mood related disorders to metabolic support and other more severe conditions as described herein. | 2011-08-25 |
20110206722 | Pharmaceutical Composition For Purifying Blood Vessels And Preparation Method Thereof - A pharmaceutical composition includes Folium Isatidis 10-30 parts, Semen Cassiae 15-35 parts, Flos Inulae 10-20 parts, Flos Carthami 15-30 parts, Flos Chrysanthemi 10-30 parts, Herba Apocyni Veneti 20-50 parts, | 2011-08-25 |
20110206723 | USE OF PLANT CELL MEMBRANE FOR THE TREATMENT OF OBESITY - The present invention relates to the use of a composition comprising at least one cell membrane fraction or parts thereof, for the reduction of lipolytic activity and/or to retard fat digestion, suppress appetite, body weight and/or lower blood lipids. The invention also relates to the use of said hydrophobic peptide in a pharmaceutical as well as a food composition and methods of treating a mammal with said composition. | 2011-08-25 |
20110206724 | HEPATITIS VIRUS CORE PROTEINS AS VACCINE PLATFORMS AND METHODS OF USE THEREOF - The present invention relates to hepatitis virus core proteins and nucleic acids. In particular, the present invention provides compositions and methods comprising recombinant hepatitis virus core proteins or nucleic acids for use in vaccine formulations. | 2011-08-25 |
20110206725 | METHOD FOR PURIFYING PROTEIN COMPLEXES - The present invention provides a method for the purification of complexes comprising a stress protein complexed to a peptide or peptide fragment, from a source mixture, typically a cell lysate. The improved method of the invention provides for protein complexes to be purified using ion exchange based methods, without the need to use chemicals such as chaotropes and ampholytes. The purified complexes can be used as the immunogenic determinant in vaccine compositions for the treatment or prevention of infectious diseases or cancerous conditions. | 2011-08-25 |
20110206726 | COMBINATION VACCINE WITH ACELLULAR PERTUSSIS - The present invention relates to a combination vaccine comprising a mixture of antigens for protection against diseases such as diphtheria, tetanus, acellular pertussis, and infections caused by | 2011-08-25 |
20110206727 | Multivalent Vaccines Based on Papaya Mosaic Virus and Uses Thereof - A multivalent vaccine composition that comprises a papaya mosaic virus (PapMV) component and one or more antigens is provided. The composition can further optionally comprise a | 2011-08-25 |
20110206728 | DNA VACCINES, USES FOR UNPROCESSED ROLLING CIRCLE AMPLIFICATION PRODUCT AND METHODS FOR MAKING THE SAME - A method of eliciting an immune response in an organism comprising: providing an unprocessed rolling circle amplification (RCA) product; and administering an effective amount of the unprocessed RCA product to the organism to elicit the immune response, wherein the unprocessed RCA product is prepared from a circular nucleic acid template comprising at least one promoter sequence, and at least one target sequence. A vaccine comprising unprocessed RCA product is also provided and methods for making the same. | 2011-08-25 |